Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

Warburg Pincus & Co (“Warburg Pincus”, USA) currently majority owns and exercises sole control, through its affiliates, over Archimedes Pharma Ltd. (“APL”, the United Kingdom). On 11 December 2009, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No. 139/2004 by which Warburg Pincus, through its affiliates, and Novo A/S ("Novo", Denmark) will acquire, within the meaning of Article 3(1)(b) of the Council Regulation, joint control over APL.

Warburg Pincus is a private equity investor.

Novo is a financial holding company, financial investor and venture capital provider.

APL and its subsidiaries comprise a European, hospital-focused, specialty pharmaceutical group, with established commercial operations and a portfolio of products marketed to specialist prescribers.

Warburg Pincus and Novo (the “Parties”) believe that the proposed concentration meets the conditions set in paragraph 5 of the Commission Notice on simplified procedure for the treatment of certain concentrations under Council Regulation (EC) No. 139/2004. The Parties to the proposed concentration have therefore requested the benefit of a Short Form CO.